Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 393769, 10 pages
http://dx.doi.org/10.4061/2011/393769
Review Article

Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson's Disease Incidence

1Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, 41012 Sevilla, Spain
2Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain

Received 12 November 2010; Accepted 21 February 2011

Academic Editor: Gilles J. Guillemin

Copyright © 2011 A. Machado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Poirier, S. Kogan, and S. Gauthier, “Environment, genetics and idiopathic Parkinson's disease,” Canadian Journal of Neurological Sciences, vol. 18, no. 1, pp. 70–76, 1991. View at Google Scholar · View at Scopus
  2. F. Tsang and T. W. Soong, “Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease,” IUBMB Life, vol. 55, no. 6, pp. 323–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. F. Allam, A. S. Del Castillo, and R. F. Navajas, “Parkinson's disease risk factors: genetic, environmental, or both?” Neurological Research, vol. 27, no. 2, pp. 206–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. C. Chung, H. W. Ko, E. Bok et al., “The role of neuroinflammation on the pathogenesis of Parkinson's disease,” BMB Reports, vol. 43, no. 4, pp. 225–232, 2010. View at Google Scholar · View at Scopus
  5. P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988. View at Google Scholar · View at Scopus
  6. E. C. Hirsch, S. Hunot, P. Damier, and B. Faucheux, “Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?” Annals of Neurology, vol. 44, no. 3, supplement 1, pp. S115–S120, 1998. View at Google Scholar · View at Scopus
  7. P. S. Whitton, “Inflammation as a causative factor in the aetiology of Parkinson's disease,” British Journal of Pharmacology, vol. 150, no. 8, pp. 963–976, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. L. McGeer and E. G. McGeer, “The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases,” Brain Research Reviews, vol. 21, no. 2, pp. 195–218, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. E. C. Hirsch, S. Hunot, B. Faucheux et al., “Dopaminergic neurons degenerate by apoptosis in Parkinson's disease,” Movement Disorders, vol. 14, no. 2, pp. 383–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Mogi and T. Nagatsu, “Neurotrophins and cytokines in Parkinson's disease,” Advances in Neurology, vol. 80, pp. 135–139, 1999. View at Google Scholar · View at Scopus
  11. A. J. Herrera, M. Tomás-Camardiel, J. L. Venero, J. Cano, and A. Machado, “Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons,” Journal of Neural Transmission, vol. 112, no. 1, pp. 111–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Nagatsu and M. Sawada, “Inflammatory process in Parkinson's disease: role for cytokines,” Current Pharmaceutical Design, vol. 11, no. 8, pp. 999–1016, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Hunot, F. Boissière, B. Faucheux et al., “Nitric oxide synthase and neuronal vulnerability in Parkinson's disease,” Neuroscience, vol. 72, no. 2, pp. 355–363, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Knott, G. Stern, and G. P. Wilkin, “Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2,” Molecular and Cellular Neuroscience, vol. 16, no. 6, pp. 724–739, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. W. D. Le, D. B. Rowe, J. Jankovic, W. Xie, and S. H. Appel, “Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells,” Archives of Neurology, vol. 56, no. 2, pp. 194–200, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu, “Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease,” Neuroscience Letters, vol. 211, no. 1, pp. 13–16, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Ferger, A. Leng, A. Mura, B. Hengerer, and J. Feldon, “Genetic ablation of tumor necrosis factor-alpha (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum,” Journal of Neurochemistry, vol. 89, no. 4, pp. 822–833, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. P. Godoy, R. Tarelli, C. C. Ferrari, M. I. Sarchi, and F. J. Pitossi, “Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease,” Brain, vol. 131, no. 7, pp. 1880–1894, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Klevenyi, O. Andreassen, R. J. Ferrante, J. R. Schleicher, R. M. Friedlander, and M. F. Beal, “Transgenic mice expressing a dominant negative mutant interleukin-1β converting enzyme show resistance to MPTP neurotoxicity,” NeuroReport, vol. 10, no. 3, pp. 635–638, 1999. View at Google Scholar · View at Scopus
  21. K. Sriram, J. M. Matheson, S. A. Benkovic, D. B. Miller, M. I. Luster, and J. P. O'Callaghan, “Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease,” The FASEB Journal, vol. 16, no. 11, pp. 1474–1476, 2002. View at Google Scholar · View at Scopus
  22. G. Banisadr, W. Rostène, P. Kitabgi, and S. M. Parsadaniantz, “Chemokines and brain functions,” Current Drug Targets: Inflammation and Allergy, vol. 4, no. 3, pp. 387–399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Cartier, O. Hartley, M. Dubois-Dauphin, and K. H. Krause, “Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases,” Brain Research Reviews, vol. 48, no. 1, pp. 16–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Biber, E. K. de Jong, H. R. J. van Weering, and H. W. G. M. Boddeke, “Chemokines and their receptors in central nervous system disease,” Current Drug Targets, vol. 7, no. 1, pp. 29–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Minami, T. Katayama, and M. Satoh, “Brain cytokines and chemokines: roles in ischemic injury and pain,” Journal of Pharmacological Sciences, vol. 100, no. 5, pp. 461–470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Nishimura, I. Mizuta, E. Mizuta, S. Yamasaki, M. Ohta, and S. Kuno, “Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease,” Neuroscience Letters, vol. 284, no. 1-2, pp. 73–76, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Schulte, L. Schöls, T. Müller, D. Woitalla, K. Berger, and R. Krüger, “Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease,” Neuroscience Letters, vol. 326, no. 1, pp. 70–72, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Nishimura, S. Kuno, I. Mizuta et al., “Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease,” Movement Disorders, vol. 18, no. 8, pp. 953–955, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Huerta, V. Álvarez, I. F. Mata et al., “Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease,” Neuroscience Letters, vol. 370, no. 2-3, pp. 151–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. O. A. Ross, C. O'Neill, I. M. Rea et al., “Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish,” Human Immunology, vol. 65, no. 4, pp. 340–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Håkansson, L. Westberg, S. Nilsson et al., “Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease,” American Journal of Medical Genetics, vol. 133, no. 1, pp. 88–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Pattarini, R. J. Smeyne, and J. I. Morgan, “Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease,” Neuroscience, vol. 145, no. 2, pp. 654–668, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Sriram, J. M. Matheson, S. A. Benkovic, D. B. Miller, M. I. Luster, and J. P. O'Callaghan, “Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α,” The FASEB Journal, vol. 20, no. 6, pp. 670–682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Sriram, D. B. Miller, and J. P. O'Callaghan, “Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α,” Journal of Neurochemistry, vol. 96, no. 3, pp. 706–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Rousselet, J. Callebert, K. Parain et al., “Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP,” Experimental Neurology, vol. 177, no. 1, pp. 183–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Leng, A. Mura, J. Feldon, and B. Ferger, “Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease,” Neuroscience Letters, vol. 375, no. 2, pp. 107–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. L. M. Bolin, I. Strycharska-Orczyk, R. Murray, J. W. Langston, and D. Di Monte, “Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice,” Journal of Neurochemistry, vol. 83, no. 1, pp. 167–175, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. Liu, Y.-H. Qiu, B. Li, S.-H. Ma, and Y.-P. Peng, “Neuroprotection of interleukin-6 against NMDA-induced apoptosis and its signal-transduction mechanisms,” Neurotoxicity Research, vol. 19, no. 3, pp. 484–495, 2011. View at Publisher · View at Google Scholar
  39. H. Chen, S. M. Zhang, M. A. Hernán et al., “Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease,” Archives of Neurology, vol. 60, no. 8, pp. 1059–1064, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Chen, E. Jacobs, M. A. Schwarzschild et al., “Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease,” Annals of Neurology, vol. 58, no. 6, pp. 963–967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Schiess, “Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away?” Archives of Neurology, vol. 60, no. 8, pp. 1043–1044, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Hernán, G. Logroscino, and L. A. García Rodríguez, “Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease,” Neurology, vol. 66, no. 7, pp. 1097–1099, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. D. B. Hancock, E. R. Martin, J. M. Stajich et al., “Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease,” Archives of Neurology, vol. 64, no. 4, pp. 576–580, 2007. View at Google Scholar · View at Scopus
  44. T. G. Ton, S. R. Heckbert, W. T. Longstreth et al., “Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease,” Movement Disorders, vol. 21, no. 7, pp. 964–969, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Ferger, P. Teismann, C. D. Earl, K. Kuschinsky, and W. H. Oertel, “Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 360, no. 3, pp. 256–261, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Sairam, K. S. Saravanan, R. Banerjee, and K. P. Mohanakumar, “Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats,” Brain Research, vol. 966, no. 2, pp. 245–252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. D. S. Maharaj, K. S. Saravanan, H. Maharaj, K. P. Mohanakumar, and S. Daya, “Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats,” Neurochemistry International, vol. 44, no. 5, pp. 355–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. D. C. Wu, V. Jackson-Lewis, M. Vila et al., “Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease,” The Journal of Neuroscience, vol. 22, no. 5, pp. 1763–1771, 2002. View at Google Scholar · View at Scopus
  49. A. Castaño, A. J. Herrera, J. Cano, and A. Machado, “Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system,” Journal of Neurochemistry, vol. 70, no. 4, pp. 1584–1592, 1998. View at Google Scholar · View at Scopus
  50. A. Castaño, A. J. Herrera, J. Cano, and A. Machado, “The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-α IL-1β IFN-γ,” Journal of Neurochemistry, vol. 81, no. 1, pp. 150–157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. A. J. Herrera, A. Castaño, J. L. Venero, J. Cano, and A. Machado, “The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system,” Neurobiology of Disease, vol. 7, no. 4, pp. 429–447, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. A. J. Herrera, R. M. De Pablos, E. Carreño-Müller et al., “The intrastriatal injection of thrombin in rat induced a retrograde apoptotic degeneration of nigral dopaminergic neurons through synaptic elimination,” Journal of Neurochemistry, vol. 105, no. 3, pp. 750–762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Carreño-Müller, A. J. Herrera, R. M. de Pablos et al., “Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia,” Journal of Neurochemistry, vol. 84, no. 5, pp. 1201–1214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. W. G. Kim, R. P. Mohney, B. Wilson, G. H. Jeohn, B. Liu, and J. S. Hong, “Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia,” The Journal of Neuroscience, vol. 20, no. 16, pp. 6309–6316, 2000. View at Google Scholar · View at Scopus
  55. R. M. De Pablos, A. J. Herrera, R. F. Villarán, J. Cano, and A. Machado, “Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra,” The FASEB Journal, vol. 19, no. 3, pp. 407–409, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. R. M. de Pablos, R. F. Villarán, S. Argüelles et al., “Stress increases vulnerability to inflammation in the rat prefrontal cortex,” The Journal of Neuroscience, vol. 26, no. 21, pp. 5709–5719, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Tomás-Camardiel, I. Rite, A. J. Herrera et al., “Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system,” Neurobiology of Disease, vol. 16, no. 1, pp. 190–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. D. C. Hernández-Romero, S. Argüelles, R. F. Villarán et al., “Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide,” Journal of Neurochemistry, vol. 105, no. 2, pp. 445–459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Argüelles, A. J. Herrera, E. Carreño-Müller et al., “Degeneration of dopaminergic neurons induced by thrombin injection in the substantia nigra of the rat is enhanced by dexamethasone: role of monoamine oxidase enzyme,” NeuroToxicology, vol. 31, no. 1, pp. 55–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. R. F. Villarán, R. M. de Pablos, S. Argüelles et al., “The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat,” NeuroToxicology, vol. 30, no. 3, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Critchley, “Medical aspects of boxing, particularly from a neurological standpoint,” British Medical Journal, vol. 1, no. 5015, pp. 357–362, 1957. View at Google Scholar
  62. A. H. Roberts, Brain Damage in Boxers. A Study of Prevalence of Traumatic Encephalopathy among Ex-Professional Boxers, Pitman Medical, London, UK, 1969.
  63. I. R. Casson, O. Siegel, and R. Sham, “Brain damage in modern boxers,” Journal of the American Medical Association, vol. 251, no. 20, pp. 2663–2667, 1984. View at Publisher · View at Google Scholar
  64. A. Guterman and R. W. Smith, “Neurological sequelae of boxing,” Sports Medicine, vol. 4, no. 3, pp. 194–210, 1987. View at Google Scholar · View at Scopus
  65. J. H. Friedman, “Progressive parkinsonism in boxers,” Southern Medical Journal, vol. 82, no. 5, pp. 543–546, 1989. View at Google Scholar · View at Scopus
  66. H. Clausen, P. McCrory, and V. Anderson, “The risk of chronic traumatic brain injury in professional boxing: change in exposure variables over the past century,” British Journal of Sports Medicine, vol. 39, no. 9, pp. 661–664, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. D. J. Loane and K. R. Byrnes, “Role of microglia in neurotrauma,” Neurotherapeutics, vol. 7, no. 4, pp. 366–377, 2010. View at Publisher · View at Google Scholar
  68. B. O. Popescu, E. C. Toescu, L. M. Popescu et al., “Blood-brain barrier alterations in ageing and dementia,” Journal of the Neurological Sciences, vol. 283, no. 1-2, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Kortekaas, K. L. Leenders, J. C. H. van Oostrom et al., “Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo,” Annals of Neurology, vol. 57, no. 2, pp. 176–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. B. A. Faucheux, A. M. Bonnet, Y. Agid, and E. C. Hirsch, “Blood vessels change in the mesencephalon of patients with Parkinson's disease,” The Lancet, vol. 353, no. 9157, pp. 981–982, 1999. View at Google Scholar · View at Scopus
  71. T. Yasuda, M. Fukuda-Tani, T. Nihira et al., “Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease,” Experimental Neurology, vol. 206, no. 2, pp. 308–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Rite, A. Machado, J. Cano, and J. L. Venero, “Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons,” Journal of Neurochemistry, vol. 101, no. 6, pp. 1567–1582, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. X. Chen, X. Lan, I. Roche, R. Liu, and J. D. Geiger, “Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum,” Journal of Neurochemistry, vol. 107, no. 4, pp. 1147–1157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Yan, M. Castillo-Meléndez, T. Nicholls, J. Hirst, and D. Walker, “Cerebrovascular responses in the fetal sheep brain to low-dose endotoxin,” Pediatric Research, vol. 55, no. 5, pp. 855–863, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. P. L. McGeer, S. Itagaki, H. Akiyama, and E. G. McGeer, “Rate of cell death in parkinsonism indicates active neuropathological process,” Annals of Neurology, vol. 24, no. 4, pp. 574–576, 1988. View at Google Scholar · View at Scopus
  76. K. A. Ji, M. S. Yang, H. K. Jeong et al., “Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain,” Glia, vol. 55, no. 15, pp. 1577–1588, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Brochard, B. Combadière, A. Prigent et al., “Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease,” The Journal of Clinical Investigation, vol. 119, no. 1, pp. 182–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Esposito, V. Di Matteo, A. Benigno, M. Pierucci, G. Crescimanno, and G. Di Giovanni, “Non-steroidal anti-inflammatory drugs in Parkinson's disease,” Experimental Neurology, vol. 205, no. 2, pp. 295–312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. R. S. Tilvis, M. H. Kähönen-Väre, J. Jolkkonen, J. Valvanne, K. H. Pitkala, and T. E. Strandberg, “Predictors of cognitive decline and mortality of aged people over a 10-year period,” The Journals of Gerontology Series A, vol. 59, no. 3, pp. 268–274, 2004. View at Google Scholar · View at Scopus
  80. S. Serres, D. C. Anthony, Y. Jiang et al., “Systemic inflammatory response reactivates immune-mediated lesions in rat brain,” The Journal of Neuroscience, vol. 29, no. 15, pp. 4820–4828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. R. R. Strang, “The association of gastro-duodenal ulceration with Parkinson's disease,” The Medical Journal of Australia, vol. 310, pp. 842–843, 1965. View at Google Scholar · View at Scopus
  82. R. J. Dobbs, S. M. Dobbs, C. Weller et al., “Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism,” Helicobacter, vol. 10, no. 4, pp. 267–275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Cunningham, D. C. Wilcockson, S. Campion, K. Lunnon, and V. H. Perry, “Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration,” The Journal of Neuroscience, vol. 25, no. 40, pp. 9275–9284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. H. M. Gao, J. S. Hong, W. Zhang, and B. Liu, “Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease,” The Journal of Neuroscience, vol. 23, no. 4, pp. 1228–1236, 2003. View at Google Scholar · View at Scopus
  85. H.-M. Gao, B. Liu, W. Zhang, and J.-S. Hong, “Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease,” The FASEB Journal, vol. 17, no. 13, pp. 1957–1959, 2003. View at Publisher · View at Google Scholar
  86. C. M. Long-Smith, L. Collins, A. Toulouse, A. M. Sullivan, and Y. M. Nolan, “Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro,” Journal of Neuroimmunology, vol. 226, no. 1-2, pp. 20–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Zhang, K. M. Lokuta, D. E. Turner, and B. Liu, “Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia,” Journal of Neurochemistry, vol. 112, no. 2, pp. 434–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. B. Koprich, C. Reske-Nielsen, P. Mithal, and O. Isacson, “Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease,” Journal of Neuroinflammation, vol. 5, article 8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. E. N. Mangano and S. Hayley, “Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: neuroimmune sensitization of neurodegeneration,” Neurobiology of Aging, vol. 30, no. 9, pp. 1361–1378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. R. F. Villarán, A. M. Espinosa-Oliva, M. Sarmiento et al., “Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease,” Journal of Neurochemistry, vol. 114, no. 6, pp. 1687–1700, 2010. View at Publisher · View at Google Scholar
  91. I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice,” Gastroenterology, vol. 98, no. 3, pp. 694–702, 1990. View at Google Scholar · View at Scopus
  92. E. Gaudio, G. Taddei, A. Vetuschi et al., “Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects,” Digestive Diseases and Sciences, vol. 44, no. 7, pp. 1458–1475, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. M. C. Pott Godoy, C. C. Ferrari, and F. J. Pitossi, “Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression,” Journal of Neuroimmunology, vol. 222, no. 1-2, pp. 29–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. C. C. Ferrari, M. C. Pott Godoy, R. Tarelli, M. Chertoff, A. M. Depino, and F. J. Pitossi, “Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra,” Neurobiology of Disease, vol. 24, no. 1, pp. 183–193, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. P. M. Carvey, E. Y. Chen, J. W. Lipton, C. W. Tong, Q. A. Chang, and Z. D. Ling, “Intra-parenchymal injection of tumor necrosis factor-α and interleukin 1-β produces dopamine neuron loss in the rat,” Journal of Neural Transmission, vol. 112, no. 5, pp. 601–612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. D. A. Gayle, Z. Ling, C. Tong, T. Landers, J. W. Lipton, and P. M. Carvey, “Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide,” Brain Research. Developmental Brain Research, vol. 133, no. 1, pp. 27–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. M. K. McCoy, T. N. Martinez, K. A. Ruhn et al., “Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease,” The Journal of Neuroscience, vol. 26, no. 37, pp. 9365–9375, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Y. Lee, Y. J. Oh, and B. K. Jin, “Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways,” Glia, vol. 51, no. 2, pp. 98–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Takeuchi, S. Jin, J. Wang et al., “Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner,” The Journal of Biological Chemistry, vol. 281, no. 30, pp. 21362–21368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. A. L. De Lella Ezcurra, M. Chertoff, C. Ferrari, M. Graciarena, and F. Pitossi, “Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation,” Neurobiology of Disease, vol. 37, no. 3, pp. 630–640, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. A. M. van Dam, J. G. J. M. Bol, R. P. A. Gaykema et al., “Vagotomy does not inhibit high dose lipopolysaccharide-induced interleukin-1β immunoreactivity in rat brain and pituitary gland,” Neuroscience Letters, vol. 285, no. 3, pp. 169–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Ek, D. Engblom, S. Saha, A. Blomqvist, P.-J. Jakobsson, and A. Ericsson-Dahlstrand, “Pathway across the blood-brain barrier,” Nature, vol. 410, no. 6827, pp. 430–431, 2001. View at Google Scholar
  103. C. A. Hathaway, C. B. Appleyard, W. H. Percy, and J. L. Williams, “Experimental colitis increases blood-brain barrier permeability in rabbits,” American Journal of Physiology, vol. 276, no. 5, part 1, pp. G1174–G1180, 1999. View at Google Scholar · View at Scopus
  104. S. S. Natah, A. Mouihate, Q. J. Pittman, and K. A. Sharkey, “Disruption of the blood-brain barrier during TNBS colitis,” Neurogastroenterology and Motility, vol. 17, no. 3, pp. 433–446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Reyes Jr., Y. Wu, Q. Lai et al., “Early inflammatory response in rat brain after peripheral thermal injury,” Neuroscience Letters, vol. 407, no. 1, pp. 11–15, 2006. View at Publisher · View at Google Scholar
  106. H. E. De Vries, M. C. M. Blom-Roosemalen, M. van Oosten et al., “The influence of cytokines on the integrity of the blood-brain barrier in vitro,” Journal of Neuroimmunology, vol. 64, no. 1, pp. 37–43, 1996. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Stanimirovic and K. Satoh, “Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation,” Brain Pathology, vol. 10, no. 1, pp. 113–126, 2000. View at Google Scholar · View at Scopus
  108. M. A. Petty and J. G. Wettstein, “Elements of cerebral microvascular ischaemia,” Brain Research Reviews, vol. 36, no. 1, pp. 23–34, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. J. B. Dietrich, “The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier,” Journal of Neuroimmunology, vol. 128, no. 1-2, pp. 58–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. J. E. Merrill and S. P. Murphy, “Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species,” Brain, Behavior, and Immunity, vol. 11, no. 4, pp. 245–263, 1997. View at Publisher · View at Google Scholar · View at Scopus
  111. N. J. Abbott, “Inflammatory mediators and modulation of blood-brain barrier permeability,” Cellular and Molecular Neurobiology, vol. 20, no. 2, pp. 131–147, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. P. F. Stahel, E. Shohami, F. M. Younis et al., “Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines,” Journal of Cerebral Blood Flow and Metabolism, vol. 20, no. 2, pp. 369–380, 2000. View at Google Scholar · View at Scopus
  113. E. Farkas, G. I. de Jong, R. A. I. de Vos, E. N. H. Jansen Steur, and P. G. M. Luiten, “Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease,” Acta Neuropathologica, vol. 100, no. 4, pp. 395–402, 2000. View at Google Scholar · View at Scopus
  114. J. D. Adams Jr., L. K. Klaidman, I. N. Odunze, and J. N. Johannessen, “Effects of MPTP on the cerebrovasculature,” International Journal of Developmental Neuroscience, vol. 9, no. 2, pp. 155–159, 1991. View at Publisher · View at Google Scholar · View at Scopus
  115. C. Zhao, Z. Ling, M. B. Newman, A. Bhatia, and P. M. Carvey, “TNF-α knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice,” Neurobiology of Disease, vol. 26, no. 1, pp. 36–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Hunot, N. Dugas, B. Faucheux et al., “FcεRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells,” The Journal of Neuroscience, vol. 19, no. 9, pp. 3440–3447, 1999. View at Google Scholar · View at Scopus
  117. T. A. Springer, “Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm,” Cell, vol. 76, no. 2, pp. 301–314, 1994. View at Publisher · View at Google Scholar · View at Scopus
  118. N. van Rooijen, “The liposome-mediated macrophage 'suicide' technique,” Journal of Immunological Methods, vol. 124, no. 1, pp. 1–6, 1989. View at Google Scholar · View at Scopus
  119. N. van Rooijen, A. Sanders, and T. K. van den Berg, “Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine,” Journal of Immunological Methods, vol. 193, no. 1, pp. 93–99, 1996. View at Publisher · View at Google Scholar · View at Scopus
  120. G. A. P. Nieuwenhuijzen, M. F. C. M. Knapen, T. Hendriks, N. van Rooijen, and R. J. A. Goris, “Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice,” Archives of Surgery, vol. 132, no. 5, pp. 533–539, 1997. View at Google Scholar · View at Scopus
  121. J. Miklossy, D. D. Doudet, C. Schwab, S. Yu, E. G. McGeer, and P. L. McGeer, “Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys,” Experimental Neurology, vol. 197, no. 2, pp. 275–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. J. R. Warren and B. Marshall, “Unidentified curved bacilli on gastric epithelium in active chronic gastritis,” The Lancet, vol. 1, no. 8336, pp. 1273–1275, 1983. View at Google Scholar
  123. C. Weller, N. Oxlade, S. M. Dobbs, R. J. Dobbs, A. Charlett, and I. T. Bjarnason, “Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism,” FEMS Immunology and Medical Microbiology, vol. 44, no. 2, pp. 129–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. F. Megraud, “Epidemiology of Helicobacter pylori infection,” Gastroenterology Clinics of North America, vol. 22, no. 1, pp. 73–88, 1993. View at Google Scholar · View at Scopus
  125. P. Ernst, “Review article: the role of inflammation in the pathogenesis of gastric cancer,” Alimentary Pharmacology & Therapeutics, vol. 13, supplement 1, pp. 13–18, 1999. View at Google Scholar · View at Scopus
  126. T. Shimada and A. Terano, “Chemokine expression in Helicobacter pylori-infected gastric mucosa,” Journal of Gastroenterology, vol. 33, no. 5, pp. 613–617, 1998. View at Publisher · View at Google Scholar · View at Scopus
  127. R. M. Peek, “Helicobacter pylori strain-specific activation of signal transduction cascades related to gastric inflammation,” American Journal of Physiology, vol. 280, no. 4, pp. G525–G530, 2001. View at Google Scholar · View at Scopus
  128. S. Aydemir, I. O. Tekin, G. Numanoglu, A. Borazan, and Y. Ustundag, “Eosinophil infiltration, gastric juice and serum eosinophil cationic protein levels in Helicobacter pylori-associated chronic gastritis and gastric ulcer,” Mediators of Inflammation, vol. 13, no. 5-6, pp. 369–372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. V. Supajatura, H. Ushio, A. Wada et al., “Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines,” Journal of Immunology, vol. 168, no. 6, pp. 2603–2607, 2002. View at Google Scholar · View at Scopus
  130. S. Brandt, T. Kwok, R. Hartig, W. König, and S. Backert, “NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9300–9305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. R. T. Ravenholt and W. H. Foege, “1918 influenza, encephalitis lethargica, parkinsonism,” The Lancet, vol. 2, no. 8303, pp. 860–864, 1982. View at Google Scholar · View at Scopus
  132. K. C. Lo, J. F. Geddes, R. S. Daniels, and J. S. Oxford, “Lack of detection of influenza genes in archived formalin-fixed, paraffin wax-embedded brain samples of encephalitis lethargica patients from 1916 to 1920,” Virchows Archiv, vol. 442, no. 6, pp. 591–596, 2003. View at Google Scholar · View at Scopus
  133. I. A. Clark, “The advent of the cytokine storm,” Immunology and Cell Biology, vol. 85, no. 4, pp. 271–273, 2007. View at Publisher · View at Google Scholar
  134. L. Qin, X. Wu, M. L. Block et al., “Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration,” Glia, vol. 55, no. 5, pp. 453–462, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. Z. D. Ling, Q. Chang, J. W. Lipton, C. W. Tong, T. M. Landers, and P. M. Carvey, “Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain,” Neuroscience, vol. 124, no. 3, pp. 619–628, 2004. View at Publisher · View at Google Scholar · View at Scopus